Paul Angelico

Executive Vice President and Chief Operations Officer at Chembio Diagnostic Systems, Inc. at Chembio Diagnostics - Medford, NY, US

Paul Angelico's Colleagues at Chembio Diagnostics
Frank Marchese

Environment, Health and Safety Manager

Contact Frank Marchese

Lu Bai

Senior Scientist

Contact Lu Bai

Eric Stobbe

Senior Cost and Financial Planning Analyst

Contact Eric Stobbe

Charles Caso

Vice President, Sales & Marketing

Contact Charles Caso

View All Paul Angelico's Colleagues
Paul Angelico's Contact Details
HQ
631-924-1135
Location
Stony Brook, New York, United States
Company
Chembio Diagnostics
Paul Angelico's Company Details
Chembio Diagnostics logo, Chembio Diagnostics contact details

Chembio Diagnostics

Medford, NY, US • 100 - 249 Employees
Medical Equipment

About Chembio Diagnostics:Chembio is a leading point-of-care diagnostics company focused on detecting and diagnosing infectious diseases, including COVID-19, sexually transmitted disease, and fever and tropical disease. Coupled with Chembio's extensive scientific expertise, its novel DPP® technology offers broad market applications beyond infectious disease. Chembio's products are sold globally, directly and through distributors, to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers. Learn more at www.chembio.com.About the DPP Rapid Test Platform:Chembio's proprietary DPP® technology platform provides high-quality, rapid diagnostic results in 15 to 20 minutes using a small drop of blood from the fingertip or alternative samples. Through advanced multiplexing, the DPP platform can detect up to eight, distinct test results from a single patient sample, delivering greater clinical value than other rapid tests. For certain applications, Chembio's easy-to-use, highly portable, battery-operated DPP Micro Reader optical analyzer then reports accurate results in approximately 15 seconds, making it well-suited for decentralized testing where real-time results enable patients to be clinically assessed while they are still on-site. Objective results produced by the DPP Micro Reader reduce the possibility of the types of human error that can be experienced in the visual interpretations required by many rapid tests.Chembio's portfolio of DPP-based point-of-care tests with FDA regulatory approvals include the DPP HIV-Syphilis System (PMA approved), DPP HIV 1/2 Assay (PMA approved and CLIA waived), DPP Zika IgM System (510(k)), and DPP Ebola Antigen System (EUA). Additionally, DPP-based tests have received regulatory approvals from the World Health Organization, CE-Mark, Agência Nacional de Vigilância Sanitária (ANVISA), and other global organizations.

B2B Biotechnology Healthcare Medical Devices Medical Diagnostics Pharmaceuticals Medical Equipment Medical and Hospital Equipment Research Development Business Services
Details about Chembio Diagnostics
Frequently Asked Questions about Paul Angelico
Paul Angelico currently works for Chembio Diagnostics.
Paul Angelico's role at Chembio Diagnostics is Executive Vice President and Chief Operations Officer at Chembio Diagnostic Systems, Inc..
Paul Angelico's email address is ***@chembio.com. To view Paul Angelico's full email address, please signup to ConnectPlex.
Paul Angelico works in the Medical Equipment industry.
Paul Angelico's colleagues at Chembio Diagnostics are Frank Marchese, Marissa Matuozzi, Lu Bai, Mohammed Billah, Alexander Kozikowski, Eric Stobbe, Charles Caso and others.
Paul Angelico's phone number is 631-924-1135
See more information about Paul Angelico